Roivant Sciences Ltd (NAS:ROIV)
$ 11.94 -0.18 (-1.49%) Market Cap: 8.83 Bil Enterprise Value: 3.66 Bil PE Ratio: 2.15 PB Ratio: 1.62 GF Score: 41/100

Q2 2021 Roivant Sciences Ltd Earnings Call Transcript

Nov 15, 2021 / 01:00PM GMT
Release Date Price: $8.08 (-3.81%)
Operator

Good day, ladies and gentlemen, and welcome to the Roivant second-quarter earnings conference call. (Operator Instructions). As a reminder, this call may be recorded. I would now like to introduce your host for today's conference call, Mr. Paul Davis. You may begin.

Paul Davis
Roivant Sciences Ltd. - Chief Communications Officer

Good morning and thank you for joining today's call to discuss Roivant's second-quarter results and business update. I am Paul Davis, the head of communications at Roivant. On the call today we have Matt Gline, our Chief Executive Officer, who will be presenting.

We also have Richard Pulik, our Chief Financial Officer; Frank Torti, our Vant Chair; Eric Venker, President and Chief Operating Officer; Mayukh Sukhatme, President and Chief Investment Officer; and Todd Zavodnick, the CEO of Dermavant.

For those dialing in via conference call, you can find the slides being presented today, as well as the press release announcing these updates, on our IR website at

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot